BioMedPartners

BioMedPartners is an independent European venture capital firm based in Basel, Switzerland, specializing in early- to mid-stage investments in life sciences companies. The firm focuses on private equity investments in innovative companies addressing significant medical needs with novel technologies or products. Their geographical focus includes Switzerland and surrounding EU countries such as Germany, Austria, France, Italy, and the Benelux region. BioMedPartners primarily invests in drug development, with a lesser emphasis on diagnostics and medical technology. The firm aims to invest up to CHF 10 million over the lifetime of its portfolio companies.

Established in 2002, BioMedPartners has built a strong team of experienced industry experts and an extensive scientific network, managing over CHF 350 million in capital. Since its inception, the firm has invested in several highly innovative companies, with 22 having successfully been acquired by leading biopharma companies or having completed an IPO. Notable examples include Amal Therapeutics SA, Okairos AG, SuppreMol GmbH, Glycart Technology AG, and ESBATech AG.

The firm's investment strategy involves acting as a lead or co-lead investor, providing private equity to early- to mid-stage life sciences companies. BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe, focusing on companies with highly innovative early-stage assets and technology platforms. In February 2018, the firm announced the closing of BioMedInvest III, their third equity venture capital fund of CHF 100 million, focusing on building companies with innovative early-stage assets and technology platforms. One of the first investments of BioMedInvest III was in the Swiss immuno-oncology company Amal SA, which was acquired by Boehringer Ingelheim in June 2019.